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112 Am J PBackground: Complementary strategies to shift risk factor population distributions and target
high-risk individuals are required to reduce the burden of type 2 diabetes and cardiovascular
disease (CVD).
Purpose: To examine secular changes in glucose and CVD risk factors over 20 years during an
individual and population-based CVD prevention program in Västerbotten County, Sweden.
Methods: Population-based health promotion intervention was conducted and annual invitation
for individuals turning 40, 50, and 60 years to attend a health assessment, including an oral glucose
tolerance test, biochemical measures, and a questionnaire. Data were collected between 1991 and
2010, analyzed in 2012 and available for 120,929 individuals. Linear regression modeling examined
age-adjusted differences in CVD risk factor means over time. Data were direct-age-standardized to
compare disease prevalence.
Results: Between 1991–1995 and 2006–2010, mean age-adjusted cholesterol (men¼0.53, 95%
CI¼0.55, 0.50 mmol/L; women¼0.48, 95% CI¼0.50, 0.45 mmol/L) and systolic blood
pressure declined (men¼3.06, 95% CI¼3.43, 2.70 mm Hg; women¼5.27, 95% CI¼5.64,
4.90 mm Hg), with corresponding decreases in the age-standardized prevalence of hypertension
and hyperlipidemia. Mean age-adjusted 2-hour plasma glucose (men¼0.19, 95% CI¼0.15, 0.23
mmol/L; women¼0.08, 95% CI¼0.04, 0.11 mmol/L) and BMI increased (men¼1.12, 95% CI¼1.04,
1.21; women¼0.65, 95% CI¼0.55, 0.75), with increases in the age-standardized prevalence of
diabetes and obesity.
Conclusions: These data demonstrate the potential of combined individual- and population-based
approaches to CVD risk factor control and highlight the need for additional strategies addressing
hyperglycemia and obesity.
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rev Med 2014;46(2):112–121 & 2014 Ameindividual and population approaches—the former to
identify and intervene in those at high risk of future
disease, and the latter to instigate positive health changes
in a large percentage of the population.1–4 The Interna-
tional Diabetes Federation (IDF) endorsed this preven-
tive approach for controlling modiﬁable risk factors and
recommends targeting both people at high risk of
diabetes and the entire population.2 However, a paucity
of data support the beneﬁcial effects of a combined
individual and population approach for reducing pop-
ulation cardiovascular risk, with most data arising from
theoretical and modeling studies.2,3 This is largely due to
a lack of longitudinal population risk distribution data
and an overwhelming focus on individual high-risk
approaches to prevention.5,6 Because there is a positive
continuous relationship between glycemia and CVD riskrican Journal of Preventive Medicine  Published by Elsevier Inc.
Long et al / Am J Prev Med 2014;46(2):112–121 113that extends below the diabetic threshold,7–9 the com-
bined prevention approach holds great potential for
reducing the macro-vascular complications associated
with hyperglycemia in particular.
Data from the Västerbotten Intervention Programme
(VIP)10 provide a unique opportunity to examine tempo-
ral changes in the distributions of glucose and other
modiﬁable CVD risk factors in a Swedish middle-aged
population when a combined individual and population
prevention strategy was underway. Västerbotten County
encompasses approximately 55,000 km2 of northern
Sweden and had the highest CVD and mortality incidence
in Sweden in the 1980s.11 VIP was introduced in 1985
to reduce the morbidity and mortality associated with
diabetes and CVD.10 VIP combines population-based
health promotion strategies, such as the introduction of
a food labeling system denoting low-fat and high-ﬁber
foods, with annual invitation for inhabitants turning 40,
50, or 60 years to attend a health assessment for systematic
CVD risk factor screening and individual counseling by
trained nurses. VIP was gradually introduced throughout
Västerbotten and reached the entire middle-aged pop-
ulation by 1991.10 The aims of this study were to examine
temporal changes in (1) the population distribution of
plasma glucose, BMI, blood pressure, and cholesterol and
(2) the prevalence of diabetes, dysglycemia, hypertension,
hyperlipidemia, overweight, and obesity at a time when
the individual- and population-based VIP prevention
program was underway between 1991 and 2010.
Methods
Study Population and Data Source
Full details of the study population and VIP have been reported
elsewhere.10 Brieﬂy, annually since 1990, individuals turning 40,
50, or 60 years who live in Västerbotten County, Sweden, are
invited for a health assessment at their local primary care center.
Participation in the VIP increased from 56% in 1995 to at least
66% since 2005. Minimal differences in age and education were
observed between individuals who took part in VIP and those who
did not. Initial small differences by sex and degree of urban
residence decreased over time.12 Data were collected between 1991
and 2010, analyzed in 2012, and are available for 120,929 individuals.
Numbers attending one, two, or three health assessments were
84,225, 35,629, and 1075, respectively.Written informed consent was
obtained from VIP participants. Ethical approval was granted by the
Regional Ethical Review Board, Umeå University.
Individual Health Survey
The individual CVD risk factor screening and motivational
interviewing by trained district nurses has been described previ-
ously.10 Brieﬂy, VIP health assessments followed a detailed manual,
used by all 36 health centers, that outlined procedures for extended
examination, physician referrals, and/or counseling regardingFebruary 2014lifestyle modiﬁcation.10 Doctors were advised to follow current
guidelines regarding pharmacologic intervention. A VIP educational
seminar was attended annually by all primary care staff involved in
the health assessments and included individual health promotion
methods and any program updates. All primary care staff attended
amotivational interviewing course, which uses open questions, active
listening, and summaries to reinforce and encourage lifestyle
changes. Evaluation work suggested that individual health surveys
were important motivators of healthy lifestyle change.13
Participants attended their local health center after an overnight
fast and completed a health questionnaire that included socio-
economic and demographic status, self-reported health, and life-
style behaviors. BMI was calculated as weight (in kilograms)
divided by the square of the height (in meters). Blood pressure
(BP) was measured twice according to clinical guidelines with a
mercury sphygmomanometer and the mean value used.14 Serum
total cholesterol was analyzed from venous blood samples using
Reﬂotron bench-top analyzers (Boehringer Mannheim GmbH).15
After an overnight fast, all participants not known to have diabetes
and with fasting plasma glucose (FPG)o7.0 mmol/L were offered
an oral glucose tolerance test (OGTT) performed according to the
WHO criteria using a 75-g anhydrous glucose load.16 Glucose
concentrations were measured on capillary plasma samples using
Reﬂotron bench-top analyzers until 2004, after which Hemo-
cue bench-top analyzers were used (Quest Diagnostics).
Population-Based Prevention Program
The VIP population-based intervention aimed to raise public
awareness of CVD risk factors and lifestyle behaviors.10 Inter-
ventions were tailored to the local community and integrated into
everyday activities. They involved the whole community, from
schools to retirement homes, and included the introduction of “the
green keyhole” food-labeling system denoting low-fat and high-
ﬁber foods, development of healthy school lunches, production
and distribution of health educational materials, and health
information meetings. Local activities, local distribution of health
educational materials, and the food-labeling system were reported
as inﬂuential motivators for healthy lifestyle change.13
Measurements
Overweight was deﬁned as 25rBMIo30 and obesity as
BMIZ30.17 Hypertension was deﬁned as BPZ140/90 mm Hg18
or self-reported use of BP-lowering medication. Hypercholester-
olemia was deﬁned as cholesterol concentrationZ5.2 mmol/L19
or self-reported use of prescribed lipid-lowering medication. As
2-hour plasma glucose (PG) measurements in capillary plasma yield
higher values (on average 1.1 mmol/L) than in venous plasma,
participants were assigned using the following WHO criteria20:
impaired fasting glucose (IFG) was deﬁned as FPGZ6.1 and o7.0
mmol/L and (if measured) 2-hour PGo8.9 mmol/L; impaired
glucose tolerance (IGT) as FPGo7.0 mmol/L and 2-hour PGZ8.9
and o12.2 mmol/L; diabetes as FPGZ7.0 mmol/L and/or 2-hour
PGZ12.2 mmol/L. The diabetes deﬁnition included self-reported
diabetes and/or self-reported prescription of diabetes medication.
Statistical Analysis
Results are expressed as meanSD or number (%) where
appropriate. Linear regression modeling examined, separately for
Long et al / Am J Prev Med 2014;46(2):112–121114each gender, age-adjusted differences in the means of continuous
CVD risk factors over four calendar periods (1991–1995, 1996–
2000, 2001–2005, and 2006–2010). Bonferroni post hoc compar-
isons assessed signiﬁcant pairwise differences between calendar
periods. To account for clustered data (repeat participation of
some individuals), random-effects linear regression modeling with
variance-corrected β-coefﬁcients was used.
To examine glucose intolerance and related CVD risk factor
prevalence, data were stratiﬁed by gender and age-standardized by
the direct method using the Swedish 2011 population (Source:
Statistics Sweden; www.scb.se/default____2154.aspx). Age-speciﬁc
rates were calculated by summing the number of individuals with
diabetes in each 5-year age group and dividing by the total
population for that age group. Each age-speciﬁc rate was then
multiplied by the standard population weighting for that age group
and summed to produce the age-standardized rate. A two-sample
test of proportions was used to assess differences in prevalence
between calendar periods 1991–1995 and 2006–2010.
For all CVD risk factors, the correlation between population
mean and corresponding risk factor prevalence was used to assess
the extent to which population distributions shift as a whole
(population mean and prevalence of high risk factor values are
expected to correlate if the population distribution shifts as a
whole21). The signiﬁcance level was set at po0.05. All analyses
were performed using Stata (version 11.2) software.
Results
Population Characteristics
Table 1 presents the characteristics of 120,929 men and
women VIP participants across four calendar periods
1991–1995, 1996–2000, 2001–2005, and 2006–2010. The
mean age of participants was 49 years during 1991–1995
and 50 years during 2006–2010. The proportion of
participants with middle or high education increased
over time for both genders. Over the same calendar
period and for both genders, the proportion of current
smokers decreased, whereas the proportion of current
snuff users increased. Self-reported use of glucose-low-
ering, lipid-lowering, and anti-hypertensive medication
increased between 1991 and 2010 for both men and
women (Table 1). Mean BMI exceeded 25 across all time
periods and increased over time from 1991–1995 to
2006–2010 in both genders. Mean total cholesterol
exceeded 5.20 mmol/L across all calendar periods but
decreased over time from 1991–1995 to 2006–2010 in
both men and women.
Temporal Changes in CVD Risk Factor
Distributions
Mean age-adjusted total cholesterol fell by 0.53 mmol/L
in men and 0.48 mmol/L in women between 1991–1995
and 2006–2010 (Table 2; po0.001 for both compari-
sons). The direct age-standardized prevalence of hyper-
lipidemia decreased from 72.1% to 61.3% in men and
from 66.9% to 55.1% in women over the same period(po0.001 for both comparisons; Table 3). Similarly,
there were declines in systolic and diastolic blood
pressure (SBP and DBP; Table 2). Between 1991–1995
and 2006–2010 the mean age-adjusted decline in SBP
was 3.06 mm Hg in men and 5.27 mm Hg in women
(Table 2). Age-standardized prevalence of hypertension
decreased from 38.3% to 34.3% in men and from 33.2%
to 27.1% in women over the same time period (Table 3).
Overall, temporal trends in CVD risk factors did not
differ by SES (Appendix A, available online at www.
ajpmonline.org), and adjusting for SES did not qualita-
tively change adjusted differences in continuous CVD
risk factors over time (data not shown).
In general and regardless of the calendar period, men
had higher FPG levels and women higher 2-hour PG
levels. There were ﬂuctuations between calendar periods
in mean glucose concentrations, but on average both
fasting and 2-hour PG values increased over time in both
genders (Tables 1 and 2). Between 1991–1995 and 2006–
2010, the age-adjusted mean increase in 2-hour PG was
0.19 mmol/L in men and 0.08 mmol/L in women. Over
the same time period, the age-standardized prevalence of
diabetes increased from 4.7% to 6.5% in men and from
3.6% to 4.3% in women (Table 3). Similarly, the age-
standardized prevalence of IFG and IGT increased
signiﬁcantly in both genders over this time period
(po0.05). Mean age-adjusted BMI increased in both
men (1.12) and women (0.65) between 1991–1995 and
2006–2010 (Table 2). The direct age-standardized prev-
alence of obesity increased from 14.0% to 22.7% in men
and from 16.8% to 22.7% in women over the same period
(po0.001 for both comparisons) (Table 3).
Figure 1 shows the distribution of risk factors in their
continuous form in 1991–1995 and 2006–2010. Correla-
tion between mean total cholesterol and prevalence of
hyperlipidemia and mean SBP and the prevalence of
hypertension was high (r¼0.96 and r¼0.95, respectively),
supporting a downward shift in the entire popula-
tion distribution of cholesterol and BP between these
calendar periods. Similarly, high correlations between
mean 2-hour PG and diabetes prevalence and mean BMI
and obesity prevalence across calendar periods (r¼0.94
and r¼0.76, respectively) support an upward shift in
the whole distribution of glucose concentrations
and BMI.
Discussion
Between 1991 and 2010, a downward shift in the entire
population distribution of cholesterol and blood pressure
was observed among the middle-aged population of
Västerbotten County, with signiﬁcant decreases in mean
age-adjusted cholesterol and SBP. Over the same timewww.ajpmonline.org
Table 1. Characteristics of 120,929 Västerbotten Intervention Programme participants by calendar period and gender
1991–1995 1996–2000 2001–2005 2006–2010
Variable
Men
(n¼12,282)
Women
(n¼13,806)
Men
(n¼13,827)
Women
(n¼15,090)
Men
(n¼15,583)
Women
(n¼16,289)
Men
(n¼16,713)
Women
(n¼17,339)
Age (years) 49.1 (7.9) 49.2 (8.0) 49.6 (7.8) 49.6 (7.9) 50.2 (8.1) 50.2 (8.0) 50.4 (8.2) 50.3 (8.2)
Education,a % (n)
Low 36.8 (4,423) 36.4 (4,909) 29.7 (4,093) 27.7 (4,153) 21.3 (3,293) 19.4 (3,132) 15.4 (2,568) 13.0 (2,241)
Medium 44.7 (5,371) 40.3 (5,432) 49.7 (6,841) 44.5 (6,667) 55.3 (8,564) 47.4 (7,651) 57.6 (9,572) 47.5 (8,189)
High 18.4 (2,214) 23.3 (3,151) 20.5 (2,823) 27.8 (4,174) 23.3 (3,613) 33.2 (5,369) 27.0 (4,480) 39.5 (6,802)
Marital status: married, % (n) 82.1 (9,862) 81.9 (11,086) 81.6 (11,170) 82.1 (12,260) 79.7 (12,313) 80.7 (13,033) 78.7 (13,081) 80.3 (13,855)
Smoking status, current,
% (n)
25.8 (3,091) 27.1 (3,663) 19.8 (2,681) 23.0 (3,429) 17.6 (2,682) 20.2 (3,251) 13.7 (2,242) 15.1 (2,580)
Snuff user, current, % (n) 21.1 (2,484) 1.6 (211) 25.4 (3,410) 3.9 (571) 28.8 (4,404) 7.7 (1,228) 26.9 (4,401) 9.4 (1,590)
BMI 25.9 (3.4) 25.3 (4.2) 26.3 (3.5) 25.6 (4.4) 26.7 (3.8) 26.0 (4.6) 27.1 (4.0) 26.0 (4.9)
Fasting PG (mmol/L) 5.4 (1.1) 5.3 (1.0) 5.6 (1.0) 5.5 (0.9) 5.8 (1.1) 5.6 (0.9) 5.6 (1.2) 5.5 (0.9)
2-hour PG (mmol/L) 6.3 (1.8) 6.9 (1.6) 6.4 (1.7) 6.9 (1.5) 6.6 (1.6) 7.1 (1.5) 6.6 (1.7) 7.0 (1.5)
Total cholesterol (mmol/L) 5.9 (1.2) 5.8 (1.2) 5.7 (1.1) 5.6 (1.1) 5.3 (1.0) 5.3 (1.0) 5.4 (1.0) 5.3 (1.0)
Systolic BP (mm Hg) 126.9 (18.7) 126.9 (18.7) 129.9 (17.0) 127.2 (18.8) 128.4 (16.9) 124.7 (18.3) 128.1 (15.9) 122.8 (16.7)
Diastolic BP (mm Hg) 81.6 (10.5) 78.6 (10.5) 81.2 (10.6) 78.0 (10.6) 79.2 (10.7) 75.6 (10.6) 80.5 (10.0) 76.3 (9.9)
Prescribed medication, % (n)
Glucose-lowering drugs: yes 0.7 (85) 0.4 (51) 1.0 (134) 0.5 (81) 1.5 (234) 0.8 (134) 2.0 (332) 1.2 (197)
Lipid-lowering drugs: yes 1.3 (162) 0.6 (80) 2.7 (378) 1.1 (173) 5.2 (818) 3.0 (486) 7.8 (1,296) 4.5 (773)
Blood pressure– lowering
drugs: yes
8.6 (1,056) 9.8 (1,354) 9.8 (1,356) 11.3 (1,705) 13.4 (2,091) 14.1 (2,305) 17.8 (2,970) 16.6 (2,872)
Note: Unless otherwise speciﬁed, data represent mean (SD).
aCompletion of years in school: low¼r9; medium¼10–12, and highZ13 years
BP, blood pressure; PG, plasma glucose
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Table 2. Age-adjusted differences in continuous cardiovascular risk factors between 1991–1995 and (A) 1996–2000,
(B) 2001–2005, and (C) 2006–2010
Risk factor β-coefﬁcients (95% CI)a
Variable A B C p-valueb
Men
Fasting PG (mmol/L) 0.16 (0.13, 0.19) 0.32 (0.29, 0.34) 0.11 (0.80, 0.13) A***, B***, C***, D***,
E***, F***
2-hour PG (mmol/L) 0.07 (0.02, 0.11) 0.26 (0.22, 0.30) 0.19 (0.15, 0.23) A*, B***, C***, D***,
E***, F***
BMI 0.39 (0.31, 0.48) 0.78 (0.71, 0.85) 1.12 (1.04, 1.21) A***, B***, C***, D***,
E***, F***
Cholesterol (mmol/L) 0.17 (0.20, 0.15) 0.61 (0.63, 0.58) 0.53 (0.55, 0.50) A***, B***, C***, D***,
E***, F***
Systolic BP (mm Hg) 0.60 (0.99, 0.22) 2.56 (2.90, 2.22) 3.06 (3.43, 2.70) A*, B***, C***, D***,
E***, F*
Diastolic BP (mm Hg) 0.55 (0.80, 0.30) 2.75 (2.97, 2.53) 1.46 (1.70, 1.23) A***, B***, C***, D***,
E***, F***
Women
Fasting PG (mmol/L) 0.13 (0.11, 0.15) 0.25 (0.23, 0.27) 0.12 (0.10, 0.14) A***, B***, C***, D***,
ENS, F***
2-hour PG (mmol/L) 0.06 (0.02, 0.10) 0.17 (0.14, 0.20) 0.08 (0.04, 0.11) A**, B***, C***, D***,
ENS, F***
BMI 0.29 (0.20, 0.39) 0.51 (0.43, 0.59) 0.65 (0.55, 0.75) A***, B***, C***, D***,
E***, F**
Cholesterol (mmol/L) 0.16 (0.18, 0.13) 0.55 (0.57, 0.53) 0.48 (0.50, 0.45) A***, B***, C***, D***,
E***, F***
Systolic BP (mm Hg) 0.18 (0.57, 0.21) 3.27 (3.60, 2.93) 5.27 (5.64, 4.90) ANS, B***, C***, D***,
E***, F***
Diastolic BP (mm Hg) 0.75 (0.99, 0.52) 3.34 (3.54, 3.14) 2.71 (2.92, 2.49) A***, B***, C***, D***,
E***, F***
Note: β-coefﬁcients (95% CIs) are presented separately by gender.
aAll regression models adjusted for age and clustering by VIP participant
bBonferroni post hoc comparisons indicated signiﬁcant pair-wise differences between calendar periods: A, 1991–1995 and 1996–2000; B, 1991–
1995 and 2001–2005; C, 1991–1995 and 2006–2010; D, 1996–2000 and 2001–2005; E, 1996–2000 and 2006–2010; and F, 2001–2005 and
2006–2010, with signiﬁcance levels indicated by *po0.05, **po0.001, ***po0.0001
BP, blood pressure; PG, plasma glucose; VIP, Västerbotten Intervention Programme
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glucose concentrations and BMI was observed, with
signiﬁcant increases in mean glucose and BMI levels.
Alongside these population shifts, there were corre-
sponding decreases in the age-standardized prevalence
of hypertension and hyperlipidemia and increases in the
prevalence of type 2 diabetes and obesity. The correlation
between mean risk factor level and prevalence of the
associated disease state across calendar periods was
strong, supporting a shift in the age-standardized pop-
ulation distribution as a whole.21 It is likely that the
combination of individual high-risk and population-
based strategies employed by the VIP contributed to
improvements in the population risk proﬁle ofcholesterol and BP. However, Northern Sweden faces a
continued public health challenge in relation to the
burden of disease associated with rising obesity and
glucose concentrations.
Traditional preventive approaches often focus on
targeting the high-risk minority. However, the majority
of people exposed to low risk will experience more
cardiovascular events than few people exposed to high
risk.4 Consequently, there is a growing realization that
complementary strategies, targeting high-risk individuals
and the entire population, are needed to shift population
risk factor distributions.1–3 Population-based strategies
targeting the underlying determinants of disease are
predicted to exert larger, cheaper, and more sustainablewww.ajpmonline.org
Table 3. Direct age-standardized prevalence of glucose tolerance and cardiovascular risk factors of Västerbotten Intervention
Programme participants
Calendar period
Variablea 1991–1995 1996–2000 2001–2005 2006–2010 p-valueb
Men (n) 12,282 13,827 15,583 16,713
Diabetes 4.7 (4.3, 5.1) 4.7 (4.4, 5.1) 6.4 (6.1, 6.8) 6.5 (6.2, 6.9) o0.0001
IFG 6.7 (6.3, 7.2) 8.9 (8.4, 9.3) 14.8 (14.3, 15.4) 8.1 (7.8, 8.5) o0.0001
IGT 3.9 (3.5, 4.2) 3.7 (3.3, 4.0) 5.0 (4.6, 5.3) 5.5 (5.1, 5.8) o0.0001
Dysglycemia 15.2 (14.5, 15.8) 17.0 (16.4, 17.6) 25.9 (25.2, 26.6) 19.8 (19.2, 20.3) o0.0001
Hypertension 38.3 (37.5, 39.1) 36.7 (35.9, 37.4) 33.4 (32.7, 34.1) 34.3 (33.6, 34.9) o0.0001
Hyperlipidemia 72.1 (70.4, 72.0) 68.9 (68.2, 69.7) 55.9 (55.1, 56.7) 61.3 (60.5, 61.9) o0.0001
Overweight 50.9 (50.1, 51.8) 56.0 (55.2, 56.8) 52.5 (51.7, 53.3) 52.7 (51.9, 53.5) 0.003
Obese 14.0 (13.5, 14.7) 19.8 (19.1, 20.5) 19.7 (19.1, 20.3) 22.7 (22.1, 23.4) o0.0001
Women (n) 13,806 15,090 16,289 17,339
Diabetes 3.6 (3.3, 3.9) 3.4 (3.1, 3.7) 4.2 (4.0, 4.6) 4.3 (4.0, 4.6) 0.0031
IFG 4.9 (4.6, 5.3) 6.0 (5.6, 6.4) 10.2 (9.7, 10.7) 7.0 (6.6, 7.4) o0.0001
IGT 5.8 (5.4, 6.2) 5.7 (5.3, 6.1) 6.5 (6.1, 6.9) 6.5 (6.1, 6.8) 0.020
Dysglycemia 14.3 (13.7, 14.8) 15.0 (14.4, 15.6) 21.0 (20.2, 21.4) 17.5 (16.9, 18.0) o0.0001
Hypertension 33.2 (32.5, 33.9) 33.0 (32.3, 33.7) 28.7 (28.1, 29.3) 27.1 (26.5, 27.7) o0.0001
Hyperlipidemia 66.9 (66.1, 67.6) 63.8 (63.0, 64.5) 51.8 (51.1, 52.5) 55.5 (54.8, 56.2) o0.0001
Overweight 36.2 (35.4, 37.0) 40.3 (39.5, 41.1) 36.3 (35.6, 37.0) 37.2 (36.5, 38.0) 0.056
Obese 16.8 (16.1, 17.4) 21.7 (21.0, 22.3) 19.4 (18.8, 20.0) 22.7 (22.0, 23.3) o0.0001
Note: Age standardization was carried out using the direct method and the Swedish population on December 31st 2011 as the standard population
(source: Statistics Sweden). Data are prevalence (95% CI).
aFull details on cut-offs used for categorizing glucose tolerance and CVD risk factors are presented in the Methods section
bImmediate form of the two-sample test of proportions was used to assess differences between calendar periods 1991–1995 and 2006–2010
IFG, impaired fasting glucose; IGT, impaired glucose tolerance
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number of high-risk individuals.22,23 In Västerbotten
County, glucose concentrations and BMI increased, not
because the high-risk minority (right-hand tail of the
population distribution) greatly increased their risk but
because the whole population distribution moved
upwards.21 A similar reverse argument applies to the
downward shift in population levels of cholesterol and
BP. Given that the association between hyperglycemia
and CVD extends below the diabetes diagnostic thresh-
old,7–9 continued individual and additional population
strategies to curb increases in glucose and BMI are
needed. Mass exposure controls, such as ﬁscal strategies
for unhealthy foods or population health promotion
programs, such as those employed in VIP, could change
cultural norms and other underlying determinants of risk
factor distributions and may exert additional effects on
population health.February 2014Comparison with Other Studies
Declining levels of total cholesterol and BP were found in
more than 66% of the 38 populations participating in
WHO MONICA (MONItoring of trends and determi-
nants in CArdiovascular disease) project from 1979 to
1996.24 This reﬂects wider Western secular trends in
which declines in cholesterol, BP, and smoking have been
linked to a substantial reduction in CVD mortality.25,26
In the MONICA Northern Sweden population (Norbot-
ten and Västerbotten counties), repeated population
surveys revealed signiﬁcant declines of 1.8 mm Hg for
SBP and 0.8 mmol/L for total cholesterol in men, and
4.9 mm Hg and 0.9 mmol/L in women, respectively,
between 1986 and 2009.27 Secular increases in the
proportion of participants with middle- or high-
education levels,28 reductions in the prevalence of
smoking, and increases in leisure-time physical activity29
likely contribute to these secular improvements.
Figure 1. Distribution of cardiovascular risk factors in Västerbotten Intervention Programme
participants between the calendar periods 1991–1995 and 2006–2010 in men and women.
Plot (A) displays (i) cholesterol and (ii) systolic blood pressure and (B) displays (i) 2-hour plasma
glucose and (ii) BMI
Long et al / Am J Prev Med 2014;46(2):112–121118Although in the same
direction of effect, im-
provements in BP and
cholesterol in the MON-
ICA Northern Sweden
population are smaller
than those in VIP, sug-
gesting that VIP may have
affected population levels
of some CVD risk factors.
It is likely that increased
awareness, treatment, and
management of CVD risk
factors as a result of indi-
vidual VIP assessments
has contributed to im-
provements in risk factor
levels and reduced the
proportion with untreated
high levels of CVD risk
factors. In particular, in-
creases in the use of
BP-lowering14 and lipid-
lowering15 medications
and self-reported reduc-
tion in fat consumption
up to 200430 and increased
physical activity levels31
in VIP participants may
have contributed toward
improved BP and choles-
terol levels. However, the
extent to which VIP con-
tributed to improved CVD
risk factor levels cannot
be directly assessed here
because of the lack of a
suitable control group. An
earlier quasi-experimental
study comparing trends
in risk factors between
1986 and 1995 in the Väst-
erbotten municipality
where VIP was initiated,
to a comparable “control”
population not participat-
ing in VIP, found that
cholesterol and BP signif-
icantly improved in the
intervention compared to
the control population.32
This ﬁnding supports thesewww.ajpmonline.org
Long et al / Am J Prev Med 2014;46(2):112–121 119results and underlines the challenge in addressing the rising
prevalence of obesity and dysglycemia.
This ﬁnding of increasing levels of glucose intolerance
conﬁrm recent population studies in Sweden reporting
adverse trends in blood glucose concentrations33,34 and
support the worldwide trend of increasing diabetes
prevalence. Increases in diabetes prevalence may be due
to an increase in diabetes incidence—although increases
in incidence were not observed from 1972 to 2001 in
central Sweden35—better treatment and/or detection of
patients (e.g., as a result of screening in VIP); extended
survival of diabetes patients; or as a consequence of an
ageing population. It is also likely that rising obesity
levels in Sweden have contributed to the rise in diabe-
tes.36 Despite the rise in blood glucose concentrations,
the frequency of diabetes in Sweden is lower than in most
European countries.37 Although VIP may have attenu-
ated the increases in glucose concentrations, it is not clear
which speciﬁc aspects of the intervention program may
have contributed to this.
An increase in mean BMI, as well as the prevalence of
overweight and obesity, was observed in VIP. These
results are consistent with previous Swedish studies,38,39
including those in Northern Sweden.40,41 Again,
increases are comparatively lower than in other Western
countries. Data from theWHOMONICA project suggest
an increase of 0.5 in Northern Sweden between the early
1980s and mid-1990s compared to 1 and 1.5 in the
United Kingdom and U.S., respectively.41 Increases in
education34 and physical activity levels31 and decreases in
saturated fat intake29 could help explain the slower rise in
obesity in Västerbotten County. Again, the extent to
which such changes occurred as a result of VIP could not
be directly addressed in the present study.
Overall, previous VIP studies found that temporal
trends in CVD risk factors did not substantially differ by
SES, in agreement with these ﬁndings. Individuals from
higher SES had lower BMI, glucose, cholesterol, and BP
levels compared to lower social classes. Over calendar
time, the gaps between socioeconomic groups reduced
for BP and cholesterol but not for BMI and glu-
cose.14,15,31,40 Although minor differences in temporal
trends of CVD risk factors between SES categories were
found in the current study, overall temporal trends in risk
factors were consistent across socioeconomic categories
(Appendix A, available online at www.ajpmonline.org).
The population-wide rise in Swedish education levels
in recent decades28 may have minimized socioeconomic
disparities in CVD risk factor levels and health over
time. Differences between the ﬁndings here and
previous VIP publications likely arise from differences
in the time periods covered and in the method of
analysis.February 2014Strengths and Limitations
A major strength of VIP is the large size (n 4100,000)
and long duration of follow-up (420 years). This was
achieved by integrating VIP into primary care, which
helped facilitate data collection and long-term follow-up
and ensured generalizability to similar locations. The use
of OGTTs captured both clinically diagnosed prevalent
undiagnosed diabetes cases, as well as changes in the
population distribution of 2-hour glucose. A regular VIP
training program for healthcare personnel and standard
operating procedures ensured that measurements were
comparable across centers and over calendar time.
Limitations include the moderate participation rates
and their large annual variation, which can introduce
selection bias when nonparticipation is related to both
exposure and outcome status. There may also have been
error in the measurement of medication use, which was
taken from a self-report questionnaire. Measurement
protocols and laboratory analyses did vary over time, but
appropriate adjustments were made following repeat
testing of a sample of participants.14,15Conclusion
The introduction of an individual- and population-based
prevention program likely contributed to improvements
in cholesterol and BP among middle-aged inhabitants of
Västerbotten County, Sweden, between 1991 and 2010.
Although the prevalence of diabetes and obesity has
risen, estimates are lower than other comparative West-
ern countries. These data demonstrate the potential for a
combination of individual- and population-based pre-
vention approaches to control CVD risk factor levels and
highlight the need for additional strategies to minimize
CVD risk and address the growing burden of disease
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